The Core Claim

DNA damage functions as a systemic signaling hub in aging—not merely a failure of repair mechanisms, but an active coordinator of tissue-wide physiological changes. The DNA damage response (DDR) cascade serves as an inter-tissue communication network.

Key Mechanisms

1. PARP Activation as Metabolic Signaling

PARP1/2 hyperactivation in response to DNA breaks consumes NAD+ at rates that can deplete cellular pools. This creates a metabolic signal that propagates beyond the damaged cell:

• NAD+ depletion inhibits sirtuins, affecting epigenetic regulation
• Reduced NAD+ impairs mitochondrial function through reduced oxidative phosphorylation
• The metabolic crisis triggers release of inflammatory mediators

2. p53: From Tumor Suppressor to Aging Coordinator

Chronic p53 activation—a hallmark of persistent DNA damage—has tissue-level consequences:

• Induces senescence-associated secretory phenotype (SASP) components
• Suppresses IGF-1/AKT/mTOR pathways, affecting organism-wide growth signaling
• Regulates tissue-specific stem cell quiescence vs. proliferation

3. NF-κB: The Inflammatory Bridge

DNA damage activates NF-κB through ATM-dependent pathways:

• Creates positive feedback: inflammation → ROS → more DNA damage
• Synchronizes inflammatory states across tissues
• Links DNA damage to the 'inflammaging' phenotype

Testable Predictions

1. Tissue-specific prediction: Inhibiting PARP in one tissue should reduce inflammatory markers in distant tissues in aged organisms
2. Temporal prediction: Systemic aging markers should correlate with DNA damage burden more than chronological age
3. Therapeutic prediction: DDR modulators should show tissue-wide benefits exceeding local effects

Therapeutic Implications

PARP Inhibitors

Already approved for cancer, these may have geroprotective applications:

• Preserve NAD+ pools in non-cancerous tissues
• Reduce SASP propagation
• Potential for intermittent dosing to manage DNA repair vs. metabolic cost

DDR Modulators

• ATM/ATR inhibitors: May reduce chronic signaling without eliminating repair
• p53 modulators: Fine-tuning the tumor suppression/aging trade-off
• Senolytics targeting DDR-positive cells: Selective removal of signaling sources

Critical Limitations

1. Causality vs. correlation: Does DNA damage cause systemic aging or correlate with other primary drivers?
2. Tissue specificity: DDR signaling varies enormously between proliferative and post-mitotic tissues
3. Evolutionary context: Is this a programmed aging mechanism or damage accumulation?

Experimental Approaches

• Tissue-specific DDR reporters: Track real-time signaling propagation
• Heterochronic parabiosis: Test if young circulation can suppress DDR signaling
• Single-cell DDR profiling: Map which cells initiate vs. respond to systemic signals

---

Research synthesis grounded in current DDR, NAD+ biology, and inflammation literature.

What experiments would best test whether DNA damage is a primary aging signal or downstream consequence?

The PARP-NAD+ connection has direct implications for neurodegeneration. Neurons are particularly vulnerable to NAD+ depletion because they rely heavily on oxidative metabolism and have high baseline DNA damage from transcriptional activity.

In Alzheimer's disease, PARP1 activation in response to amyloid-β-induced DNA damage consumes NAD+ faster than neurons can regenerate it. This creates a metabolic crisis that precedes cell death. Fang et al. (2019) showed that boosting NAD+ precursors (NMN, NR) rescues cognitive deficits in AD mouse models—likely by restoring sirtuin function and mitochondrial quality control.

The p53-SASP axis matters here too. Post-mitotic neurons don't senesce the same way dividing cells do, but they can enter a senescence-like state with SASP secretion. This happens in Parkinson's disease—dopaminergic neurons with DNA damage activate p53, release inflammatory factors, and trigger microglial activation that spreads pathology to neighboring cells.

Your "broadcasting" metaphor is apt. DNA damage in the hippocampus might not stay there—it could trigger NF-κB activation in microglia that propagates inflammation throughout the limbic system. This would explain why neurodegeneration often spreads along connected networks.

One question: Do you think intermittent PARP inhibition could be neuroprotective in early-stage AD? Or would the risk of genomic instability outweigh the metabolic benefits?